Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33^{ALLO}) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation (Trial in Progress)

Nirali N. Shah¹, Jacques Azzi², Brenda Cooper³, Abhinav Deol⁴, John F. DiPersio⁵, Divya Koura⁶, Brian McClune⁷, Lori Muffly⁸, Muhammad U. Mushtaq⁹, Rupa Narayan¹⁰, Hyung C. Suh¹¹, Gregory Yanik¹², Sritama Nath¹³, Jennifer Whangbo¹³, Guenther Koehne¹⁴

School of Medicine at the University, St Louis, MO; ³University, St Louis, MO; ³University of Utah, Salt Lake City, UT; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ³University, St Louis, MO; ⁴Karmanos Cancer Institute, Detroit, MI; ⁴Karmanos Cancer Institute, Detroit, MI; ⁴Karm and Marrow Transplantation, Stanford University School of Medicine, Palo Alto, CA; ⁹Division of Hematologic Malignancies & Cellular Therapeutics, University Medical Center, Hackensack, NJ; ¹²UMHS Division of Pediatric BMT, Ann Arbor, MI; ¹³Vor Bio, Cambridge, MA; ¹⁴Miami Cancer Institute, Miami, FL

Background And Significance

- Though allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative therapy for patients with high-risk acute myeloid leukemia (AML), post-HCT relapse occurs in up to 70% of these patients¹
- Clinical experience with chimeric antigen receptor (CAR) T cell therapies for AML is limited
- Challenges for autologous AML CAR T cell therapy include:
- Difficulty harvesting adequate numbers of functional, undifferentiated T cells as CAR T cell starting material
- T cells from post-alloHCT patients may be exposed to immunosuppression, which can further reduce activity
- Presence of AML blasts in an autologous cell collection may interfere with T cell proliferation and function during the manufacturing process
- CD33 is expressed on the majority (>80%) of AML blasts and is an established target for AML therapy
- VCAR33^{ALLO} is a CD33-directed CAR T cell product generated from lymphocytes from each patient's prior matched allogeneic stem cell donor
- CAR T cell manufacture from HLA-matched donors can eliminate delays and failures in production due to lymphopenia and may also improve CAR T cell function by using healthy starting material


VCAR33^{ALLO}

lintuzumab scFv

CD28

- Allogeneic CD4+ and CD8+ T cells transduced with a replication defective lentiviral vector expressing a CAR that targets CD33²
- Lintuzumab scFv (Hu195; SGN-33): binding domain derived from unconjugated humanized murine monoclonal antibody against CD33
- CD28 and CD3ζ internal costimulatory domain
- Same CAR construct used for manufacturing autologous CD33CART in a Phase 1/2 study (NCT03971799)
- ASH abstract 771, "CD33 CAR T-cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I Multicenter Trial", Oral Presentation, Monday, December 11, 2023, 11:00 AM

In vivo Efficacy Of VCAR33^{ALLO} In A Murine Tumor Model



Representative total body bioluminescence images of NSG mice injected with MOLM13-GFP-Luc cells and treated with PBS, VCAR33^{ALLO} or UTD T Cells. Images were taken weekly starting 1 week after the inoculation of AML cells. Red crosses (x) represent animals euthanized or found dead during the study.

(Courtesy of Dr. Giacomo Canesin, Vor Biopharma)

Study Design

- VBP301 is an open-label, multicenter, phase 1/2 study (NCT05984199)
- Patients with relapsed/refractory (R/R) AML after alloHCT will be enrolled into 2 arms based on disease burden (Arm A: Morphologic disease and Arm B: MRD positive)
- VCAR33^{ALLO} will be manufactured from each patient's original matched stem cell donor and given as a one-time infusion
- The maximum tolerated dose (MTD) of VCAR33^{ALLO} will be determined using a 3+3 trial design within each arm
- Three planned dose levels, starting with Dose Level 1: 1 x 10⁶ CAR T cells/kg
- Total projected enrollment: 24-36 patients (12-18 per arm), with up to 40 additional patients into enrichment cohorts

Abbreviations: BM, bone marrow; BTMB, Be The Match BioTherapies; CNS, central nervous system; DLI, donor lymphocyte infusion; HLA, human leukocyte antigen; LD, lymphocyte infusion; HLA, human leukocyte antigen; LD, lymphodepletion; MRD, measurable residual disease; NSG, NOD-scid IL2Rynull mice; PBS, phosphate buffered saline; R/R, relapsed/refractory; UTD, untransduced References: ¹Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. J Clin Oncol. 2016;34(4):329-336; ²Qin H, Yang L, Chukinas JA, et al. J Immunother Cancer. 2021 Sep;9(9):e003149.

- CD3ζ


Key Inclusion Criteria

- Age ≥18 years
- CD33+ AML in relapse after 1st alloHCT
- Recipient of 8/8 HLA-matched related or unrelated donor alloHCT
- Patients with R/R AML after trem-cel HCT (NCT04849910) may also be considered
- Disease status:
 - <u>Arm A</u>: Morphologic disease (≥5% blasts in BM)
 - Arm B: MRD positive (<5% blasts in BM with at least 0.1% CD33+ AML by flow cytometry)
- Original donor eligible and willing to undergo non-mobilized apheresis
- Donor options for 2nd alloHCT have been identified

Key Exclusion Criteria

- Greater than 1 prior alloHCT
- <100 days post prior alloHCT at the time of VCAR33^{ALLO} infusion
- H/o Grade III-IV acute GVHD or severe chronic GVHD
- Active GVHD requiring systemic immunosuppression
- Disease status:
- Active CNS involvement with AML
- Hyperleukocytosis (≥30,000 blasts/µL) or rapidly progressive disease
- DLI within 28 days of enrollment
- Prior CAR T therapy

	C
	Objectives
Primary	Safety and maximum tolerated dose (MTD) of VCAR33 ^{ALLO} in patients with R/R AML after alloHCT
Secondary	 Evaluate further safety and toxicity of VCAR33^{ALLO} Determine the efficacy of VCAR33^{ALLO} in patients with R/R AML after alloHCT



Objectives and Endpoints

Endpoints

administered until LD.

Incidence of dose-limiting toxicities

(Inpatient)

- Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and sinusoidal occlusion syndrome (SOS) related to VCAR33^{ALLO}
- Incidence of cytopenias post-VCAR33^{ALLO} infusion
- Incidence of acute and chronic graft versus host disease related to VCAR33^{ALLO}
- Percentage of patients who achieve response by 2022 ELN criteria for AML
- Overall survival and progression-free survival post-VCAR33^{ALLO} infusion
- Frequency of patients who proceed to second alloHCT post-VCAR33^{ALLO} infusion

#293

- progressive AML

Day	Lymphodepletion
-5,-4	fludarabine 30 mg/m²/day
-3,-2	fludarabine 30 mg/m²/day + cyclophosphamide 500 mg/m²/day
-1	Rest Day
Day 0: VCAR33 ^{ALLO} Infusion	

Summary • VBP301 is an open-label, multicenter, phase 1/2 study of donor-derived anti-CD33 CAR T cells (VCAR33^{ALLO}) in patients with R/R AML after alloHCT with an 8/8 HLA-matched donor, including patients who relapse after a trem-cel transplant Patients will be enrolled into a Morphologic disease arm or an MRD positive arm • Total projected enrollment: 24-36 patients (12-18 per arm), with up to 40 additional patients into enrichment cohorts (NCT05984199)

Presented at the Tandem Meetings; February 21-24, 2024; San Antonio, USA